GPNMB⁺髓源性抑制细胞介导前列腺癌放疗免疫抑制并可靶向改善全身控制
本研究基于SBRT治疗前列腺癌患者配对外周血样本及RM-9小鼠模型,发现GPNMB⁺MDSC选择性扩增并增强T细胞抑制。阻断GPNMB可恢复T细胞活性,抗GPNMB抗体联合放疗显著改善局部控制并减少转移,优于PD-L1阻断。
要点
- SBRT后GPNMB⁺MDSC选择性扩增并增强T细胞抑制。
- 阻断GPNMB可快速恢复患者PBMC的T细胞活性。
- 抗GPNMB联合放疗改善局部控制与转移,优于PD-L1阻断。
核心结论
- 放疗诱导的MDSC→GPNMB髓系检查点抑制前列腺癌T细胞免疫,靶向该通路可逆转免疫抑制并改善全身控制。
研究设计与样本
- 使用SBRT治疗患者配对外周血样本,流式细胞术检测MDSC,并行患者PBMC体外功能实验。
- 采用同基因RM-9前列腺癌小鼠模型进一步表征,用qPCR和荧光素酶报告实验确定机制。
主要发现
- 患者SBRT后GPNMB⁺MDSC选择性且可重复地扩增,伴T细胞抑制增强。
- 患者PBMC中阻断GPNMB快速且一致地恢复T细胞活性。
- 荷瘤小鼠放疗上调MDSC的GPNMB及肿瘤浸润T细胞的配体syndecan-4。
- 抗GPNMB抗体联合放疗较单用放疗显著改善局部肿瘤控制并减少转移负荷,且优于PD-L1阻断。
- 转录组和机制分析确定MITF为放疗诱导GPNMB表达的关键调控因子。
临床怎么用
- 对局部高危前列腺癌SBRT患者,可考虑联合MDSC/GPNMB靶向治疗以逆转放疗免疫抑制并改善全身控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy (SBRT) provides excellent local control for localized prostate cancer (PC); however, systemic relapse remains the primary cause of death in high-risk patients, underscoring the need to understand and therapeutically address radiation-induced immune suppression. Here, we identify a previously unrecognized myeloid checkpoint pathway driven by glycoprotein nonmetastatic B (GPNMB⁺) myeloid-derived suppressor cells (MDSCs) as a dominant systemic response to clinical SBRT and demonstrate a tractable strategy to counter it. METHODS AND MATERIALS: We used paired peripheral blood samples from patients treated with SBRT to measure systemic MDSCs by flow cytometry, followed by ex vivo functional assays with patients' peripheral blood mononuclear cells. For further characterization, we used a syngeneic PC RM-9 tumor model. quantitative polymerase chain reaction and luciferase assays determined the mechanism observed. RESULTS: We observed a selective and reproducible expansion of GPNMB⁺ MDSCs accompanied by enhanced T-cell suppression. GPNMB blockade in patients' peripheral blood mononuclear cells rapidly and consistently restored T-cell activity, directly supporting the clinical feasibility of targeting this pathway. Likewise, in tumor-bearing mice, radiation upregulated GPNMB on MDSCs and its ligand syndecan-4 on tumor-infiltrating T cells. Therapeutically, combining anti-GPNMB antibody with radiation significantly improved local tumor control and reduced metastatic burden compared with radiation alone and outperformed programmed death-ligand 1 blockade. Transcriptomic and mechanistic analyses identified melanocyte-inducing transcription factor as a key regulator of radiation-induced GPNMB expression. CONCLUSIONS: Together, these findings define an actionable radiation therapy→ MDSC → GPNMB myeloid checkpoint that suppresses T-cell immunity in PC and demonstrate that targeting this pathway reverses radiation-induced immune suppression across human and murine systems. This work establishes a strong translational rationale for integrating MDSC-targeted therapy with SBRT to improve systemic control in localized high-risk PC.
引用
- Mulvaney O, Chung JS, Kobayashi M, et al. Glycoprotein Nonmetastatic B⁺ Myeloid-Derived Suppressor Cells Mediate Radiation-Induced Immune Suppression in Prostate Cancer and Are Targetable to Improve Systemic Control. Int J Radiat Oncol Biol Phys. 2026. PMID: 42069260. doi:10.1016/j.ijrobp.2026.04.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。